力生制药：公司属医药制造及生物医药行业

Core Viewpoint - Lisheng Pharmaceutical (002393) is a publicly listed company in the Shenzhen Stock Exchange, operating in the pharmaceutical manufacturing and biopharmaceutical industry, recognized as a national high-tech enterprise and a model enterprise for technological reform by the State-owned Assets Supervision and Administration Commission in 2022 [1] Company Overview - Established in 1951, the company focuses on drug research, production, and sales, with a product range covering 15 major categories and a total of 296 varieties [1] - The company holds 111 patent authorizations and 189 registered trademarks [1] Technological Capabilities - Lisheng Pharmaceutical has early investments in controlled-release formulations, with core technologies including a permeation pump controlled-release technology based on laser perforation [1] - This technology has been applied in products such as Doxazosin Mesylate Sustained-Release Tablets, enabling long-lasting and stable drug release [1] Production and R&D Facilities - The company has established a controlled-release formulation platform and is recognized as a key laboratory for controlled-release and solid dispersion drug formulations in Tianjin [1] - It possesses various formulation technologies, including skeleton-controlled release, sustained-release micro-particles, and solid dispersions, forming a comprehensive formulation technology system [1] Industry Position - Lisheng Pharmaceutical is one of the few companies in China capable of industrializing permeation pump controlled-release formulations, achieving breakthroughs in the localization of key equipment and excipients in the high-end formulation sector [1]